All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for ELI LILLY & COMPANY · Pharmaceutical/ Health Products

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 3

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 4818
Treat and Reduce Obesity Act of 2023
S 2407
Treat and Reduce Obesity Act of 2023

Lobbying activity 7

Defense

Issues related to pharmaceutical manufacturing and development.

Pharmacy

Drug importation, prescription drug safety, value and access.

Medicare/Medicaid

Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Trade (domestic/foreign)

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights.

Taxation/Internal Revenue Code

International and domestic tax issues. H.R. 1, One Big Beautiful Bill Act implementation.

Health Issues

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.